Avastin found effective in advanced breast cancer patients

Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer – Genentech, Inc. (NYSE: DNA) announced that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin? (bevacizumab) in combination with docetaxel chemotherapy met its primary endpoint of prolonging progression-free survival (PFS) in patients who had not received prior chemotherapy for their locally recurrent or metastatic HER2-negative breast cancer.

GVAX cancer immunotherapy improves prostate cancer survival

Interim analysis supports continuation of Cell Genesys’ VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer – Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.

Exercise may benefit older breast cancer survivors

An Oregon Health & Science University Cancer Institute study will evaluate the beneficial effects of aerobic exercise and resistance training for breast cancer survivors who are at least two years post-treatment with chemotherapy or radiation. – An Oregon Health & Science University Cancer Institute study is examining different forms of exercise for women older than 65 who have had breast cancer. Different exercises may benefit older breast cancer survivors.

Novel anti-cancer strategy moves to clinic

Emory University researchers have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells. – Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important “intercept points” for cancer cells.

New strategies work to put cancer on the firing line

Cancer cells are our own cells gone awry. That means our immune system doesn?t always see cancer as a horrific invader. – Dr. Yukai He wants to put cancer in the bull’s eye. “Cancer really comes from us,” the Medical College of Georgia Cancer Center immunologist says of the scary reality that cancer cells are our own cells gone awry. That means our immune system doesn’t always see cancer as a horrific invader.

New perspectives on health disparities in breast cancer research

Asian breast cancer women (67.5 percent) choose to have a mastectomy over lumpectomy compared to Caucasian women (57.3 percent).
– Breast cancer is a disease with a number of known genetic and behavioral risk factors, but scientists have seen that these risks are often compounded by social and racial inequalities. The question remains: how, exactly, do social disadvantages, genetics, race and culture add to the disparities faced by so many groups of women?

Health Newstrack